+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biopharmaceutical R&D Statistical Sourcebook 2018/2019

  • PDF Icon


  • 486 Pages
  • April 2018
  • Cambridge Healthtech Institute
  • ID: 4662323

The Biopharmaceutical R&D Statistical Sourcebook 2018/2019 is the leading resource for R&D statistics, trends, and proprietary market intelligence and analyses on the biopharmaceutical industry. Supported by thousands of graphs, illustrations, and analyses, the Sourcebook provides the latest intelligence on every aspect of biopharmaceutical development – from product discovery, to R&D performance and productivity, to time-to-market trends. With real-world analysis and key contributions from leading consultancies and experts, the Sourcebook includes:

  • New proprietary analysis on US clinical trial starts, segmented by therapeutic category, as well as overall active clinical trials
  • Assessments of personalized medicine/companion diagnostics, biosimilars, orphan drugs, and other factors reshaping biopharma R&D today
  • The latest analyses on clinical trial success rates, broken down by clinical trial phase and therapy area
  • All-new analyses on who “owns” today’s R&D pipeline, R&D spending, and new drug/biologics approvals by company size and type (pharma vs. biotech)
  • Emerging data on worldwide and company-specific R&D pipelines and product launch trends
  • New analyses on emerging trends in pharma and biotech licensing deals and other partnerships critical to industry’s R&D pipeline
  • Drug approval statistics compiled from FDA, EMA, and other regulatory agencies
  • New global R&D spending trends and other international R&D data from key markets

And much more:

  • Spotlight analyses on emerging and re-emerging elements of industry’s R&D pipeline, including immunooncology, microbiome R&D, and cell/gene therapy
  • Assessments of several emerging industry controversies, including drug pricing, the wisdom of ultra-rapid new drug reviews, and R&D “overcrowding” in some parts of the new drug pipeline
  • Spotlight analyses on the FDA’s expedited programs (breakthrough therapy, fast track, accelerated approval) and how their increased use is reshaping new drug development today
  • Analyses on the state, nature, and sustainability of industry’s pipeline of R&D projects
  • Analyses focused on the drug and biopharma markets and development pipelines within emerging countries, including brand new analyses on Korea and China

The Biopharmaceutical R&D Statistical Sourcebook 2018/2019 is a must-have resource for the drug development industry. It is invaluable to executives and managers working in the pharma and biotech industries. The Sourcebook puts real-world data sets at your fingertips for presentations, reports, business development efforts, strategic meetings, and critical decision-making analyses.
The 2018/2019 edition is also offered in electronic format for individual users, small groups, business units, or company-wide access.